13
Participants
Start Date
March 15, 2022
Primary Completion Date
October 17, 2023
Study Completion Date
April 29, 2024
parsaclisinib
parsaclisib will be administered QD orally
placebo
placebo will be administered QD orally follwed by Parsaclisinib in the open label period
Investigative Site US007, The Bronx
Investigative Site US002, The Bronx
Investigative Site FR003, Marseille
Investigative Site US010, Easton
Investigative Site IT002, Milan
Investigative Site IT004, Pavia
Investigative Site US003, Greenville
Investigative Site ES003, Madrid
Investigative Site IT001, Novara
Investigative Site ES005, Murcia
Investigative Site IL002, Haifa
Investigative Site US006, Miami
Investigative Site IT005, Trieste
Investigative Site US001, Knoxville
Investigative Site ES004, Tarragona
Investigative Site US009, Canton
Investigative Site DE001, Essen
Investigative Site ES002, Valencia
Investigative Site US012, Indianapolis
Investigative Site IT003, Florence
Investigative Site FR002, Lille
Investigative Site PL001, Legnica
Investigative Site FR001, Paris
Investigative Site DE002, Ulm
Investigative Site US005, Los Angeles
Investigative Site US004, Whittier
Investigative Site IL001, Nahariya
Investigative Site AT002, Salzburg CET
Investigative Site AT001, Vienna
Investigative Site BE001, La Louvière
Investigative Site BE002, Liège
Investigative Site CA001, Edmonton
Investigative Site IT006, Rome
Investigative Site JP008, Fukuoka
Investigative Site JP004, Isehara
Investigative Site JP006, Nagoya
Investigative Site JP009, Okayama
Investigative Site JP002, Okayama
Investigative Site JP010, Osakasayama-shi
Investigative Site JP005, Saitama
Investigative Site JP007, Sendai
Investigative Site JP001, Suita-shi
Investigative Site JP003, Tokyo
Investigative Site NL001, Rotterdam
Investigative Site PL006, Lodz
Investigative Site PL003, Nowy Sącz
Investigative Site PL005, Opole
Investigative Site PL004, Wałbrzych
Investigative Site PL002, Wroclaw
Investigative Site ES006, Badalona
Investigative Site ES001, Barcelona
Investigative Site GB002, Glasgow
Investigative Site GB006, London
Investigative Site GB003, Norwich
Investigative Site GB004, Plymouth
Investigative Site GB005, Reading
Lead Sponsor
Incyte Corporation
INDUSTRY